Free Trial
NASDAQ:EPRX

Eupraxia Pharmaceuticals 11/14/2023 Earnings Report

Eupraxia Pharmaceuticals logo
$3.81 -0.09 (-2.31%)
Closing price 05/21/2025 03:56 PM Eastern
Extended Trading
$3.97 +0.16 (+4.17%)
As of 05/21/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eupraxia Pharmaceuticals EPS Results

Actual EPS
-$0.26
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eupraxia Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eupraxia Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Eupraxia Pharmaceuticals' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules.

Conference Call Resources

Eupraxia Pharmaceuticals Earnings Headlines

Here’s your answer
Porter Stansberry is stepping into the spotlight — and putting real skin in the game. For the first time ever, he’s opening the doors to a live, real-money trading account, managed transparently with the same strategies he’s used to build long-term wealth. Every 90 days, he and his lead analyst release a new tranche of trades designed for serious investors who don’t want to babysit the market. The goal: income, downside protection, and asymmetric upside.
See More Eupraxia Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

View Eupraxia Pharmaceuticals Profile

More Earnings Resources from MarketBeat